Nasdaq
$3.11▲ 1.42%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $769.1MShares out 2.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 8.25After-hours26.08.26 08:194Ownership#●●●
ARDELYX, INC.
Susan Hohenleitner, an insider at Ardelyx, Inc., reported changes in her beneficial ownership of securities as of August 21, 2026. This filing is a standard Form 4 disclosure regarding the insider's equity holdings.…more
$3.11+1.42%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.25After-hours26.08.26 08:174Ownership
ARDELYX, INC.
Joseph James Reilly, an executive at Ardelyx, Inc., reported a change in beneficial ownership of company securities effective August 21, 2026. This filing serves as the official disclosure of the insider's updated securities holdings via Form 4.…more
$3.11+1.42%vs prev closeView filingShare - 8.25After-hours26.08.26 08:164Ownership
ARDELYX, INC.
Director John E. Bishop of Ardelyx, Inc. (ARDX) reported a change in his beneficial ownership of company securities on August 21, 2026. This filing serves as a standard Form 4 disclosure regarding insider stock holdings.…more
$3.11+1.42%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoAfter-hours26.10.24 05:03#●●●#●●●
Ardelyx Presents Real-World Data for XPHOZAH in Dialysis Patients
Ardelyx announced real-world analysis results at ASN Kidney Week 2026 demonstrating the efficacy of XPHOZAH in reducing serum phosphate levels among dialysis patients. The data further highlights the clinical challenges of managing hyperphosphatemia and the associated long-term health risks.…more
$3.11+1.42%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 5d agoPre-market26.10.20 20:30
●●●●●●●● ●●●●● ●●●●●●
Ardelyx announced it will host a conference call on November 3, 2026, to discuss its third-quarter financial results. This is a routine corporate announcement regarding the upcoming earnings release.…more
$3.11+1.42%vs prev close - 10.12Pre-market26.10.12 21:01
●●●●●●●● ●●●●● ●●●●●●
Ardelyx presented real-world data at ACG 2026 demonstrating that IBSRELA significantly reduces healthcare resource utilization in patients with IBS-C. While this highlights the clinical value of the drug, it does not represent a direct financial performance update, leading to a neutral outlook.…more
$3.11+1.42%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report